[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Disc Medicine Inc (IRON)

Disc Medicine Inc (IRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,604,801
  • Shares Outstanding, K 38,160
  • Annual Sales, $ 0 K
  • Annual Income, $ -212,180 K
  • EBIT $ -236 M
  • EBITDA $ -244 M
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.74

Options Overview Details

View History
  • Implied Volatility 50.69% (-0.53%)
  • Historical Volatility 30.46%
  • IV Percentile 16%
  • IV Rank 10.83%
  • IV High 131.40% on 01/20/26
  • IV Low 40.89% on 09/12/25
  • Expected Move (DTE 5) 0.68 (1.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 339
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 5,149
  • Open Int (30-Day) 4,956
  • Expected Range 67.58 to 68.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.60
  • Number of Estimates 7
  • High Estimate $-1.37
  • Low Estimate $-1.76
  • Prior Year $-1.58
  • Growth Rate Est. (year over year) -1.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.99 +5.04%
on 05/01/26
72.40 -5.72%
on 04/20/26
+1.99 (+3.00%)
since 04/08/26
3-Month
40.00 +70.65%
on 02/13/26
79.80 -14.46%
on 02/09/26
-11.46 (-14.38%)
since 02/06/26
52-Week
40.00 +70.65%
on 02/13/26
99.50 -31.40%
on 12/08/25
+23.97 (+54.12%)
since 05/08/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to...

IRON : 68.26 (+1.08%)
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

NEW YORK , May 6, 2026 /PRNewswire/ --

IRON : 68.26 (+1.08%)
Disc Medicine's Regulatory Path Forward Could Start Looking Less Hypothetical After This Quarter

Barchart Research What to Expect from IRON Earnings IRON Generated May 5, 2026 Current Price $67.59 EPS Estimate $$-1.55 Consensus Rating Strong Buy Average Move 2.79% Disc Medicine's Regulatory Path Forward...

IRON : 68.26 (+1.08%)
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with...

IRON : 68.26 (+1.08%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON).  Such investors are advised...

IRON : 68.26 (+1.08%)
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

NEW YORK , April 30, 2026 /PRNewswire/ --

IRON : 68.26 (+1.08%)
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

NEW YORK , April 25, 2026 /PRNewswire/ --

IRON : 68.26 (+1.08%)
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 68.26 (+1.08%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...

IRON : 68.26 (+1.08%)
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

NEW YORK , April 14, 2026 /PRNewswire/ -- 

IRON : 68.26 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Disc Medicine Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Disc Medicine Inc., formerly known as Gemini Therapeutics Inc., is based in WAYLAND, Mass.

See More

Key Turning Points

3rd Resistance Point 72.85
2nd Resistance Point 71.57
1st Resistance Point 69.92
Last Price 68.26
1st Support Level 66.99
2nd Support Level 65.71
3rd Support Level 64.06

See More

52-Week High 99.50
Fibonacci 61.8% 76.77
Fibonacci 50% 69.75
Last Price 68.26
Fibonacci 38.2% 62.73
52-Week Low 40.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.